Please login to the form below

Not currently logged in
Email:
Password:

Flu vaccine subsidy for Takeda

Takeda Pharmaceutical is to receive a 23.9bn Yen subsidy from the Japanese government as part of a scheme to support the development and production of new influenza vaccines

Takeda Pharmaceutical is to receive a 23.9bn Yen (€215m) subsidy from the Japanese government as part of a scheme to support the development and production of new influenza vaccines.

The company's current influenza-related projects include an agreement with Baxter International to develop the proprietary Vero cell culture-based influenza vaccine technology.

Takeda has already introduced the technology into its experimental production facilities Hikari City having received a similar subsidy in 2010.

The extra funding will enable Takeda to continue the development work it had commenced and make preparations for full-scale manufacturing, including constructing a commercial production facility at the Hikari plant.

A new drug approval for an influenza vaccine is expected by the end of the financial year 2013, according to Takeda.

23rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics